COVERAGE
Top State and Local Tax Policies of 2024: Midyear Report
July 5, 2024
Read time: 2 min

COVERAGE
July 5, 2024
Read time: 2 min

COVERAGE
July 2, 2024
Read time: 2 min

COVERAGE
July 1, 2024
Read time: 2 min

DEAL ANNOUNCEMENT / PRESS RELEASE
July 12, 2024
Read time: 3 min
Duesseldorf, July 12, 2024 – International law firm McDermott Will & Emery advises Ligand Pharmaceuticals Incorporated on the planned acquisition of all shares in the Austrian stock corporation APEIRON Biologics AG.
Upon closing of the transaction, Ligand shall acquire all the outstanding shares of APEIRON for $100 million in cash. Ligand will also pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if royalties from APEIRON’s co-developed drug QARZIBA exceed certain pre-determined thresholds by 2030 or 2034, respectively.
The transaction is expected to close in July 2024.
APEIRON is a biopharmaceutical company based in Vienna, Austria. The company holds the royalty rights to the cancer drug QARZIBA®, which it co-developed. QARZIBA was approved by the European Medicines Agency in 2017 and is now available in more than 35 countries.
Ligand Pharmaceuticals is a biopharmaceutical company that invests in the clinical development and commercialization of high value drugs. Ligand manages one of the largest biopharmaceutical royalty portfolios with more than 100 partnered programs in commercial and development stages.
The McDermott team is led by partners Uwe Goetker and Sebastian Bonk (Corporate/M&A) and comprised senior counsel Gary Howes (Corporate/M&A), counsel Marcus Fischer (U.S. & International Tax) as well as associates Sebastian Klein, Jan Lorenzen, Hubertus von Bornstaedt, and Nils Ladewig (all Corporate/M&A).

COVERAGE
July 15, 2024
Read time: 2 min

DEAL ANNOUNCEMENT / PRESS RELEASE
July 15, 2024
Read time: 4 min
International law firm McDermott Will & Emery represented Apex Clean Energy (Apex), a leader in renewable energy, in partnership with First Citizens Bank Energy Finance, on two financings totaling more than $150 million for battery energy storage projects in Texas. These are two of the largest energy storage financings under the Inflation Reduction Act (IRA) and leverage the IRA’s tax credit transferability. The facilities are:
“We are pleased to have advised on this sophisticated financing for Apex, which will optimize its capital structure and further position Apex for continued growth,” said Energy and Project Finance partner Carl Fleming. “This innovative financing leverages the tax credit transferability mechanism under the IRA and optimizes the value of the projects for Apex, one of our most valued and longstanding clients.”
“Great Kiskadee and Angelo showcase the transformative impact of the IRA on accelerating energy storage deployment,” said Kurt Friesen, Apex General Counsel. “McDermott’s expertise and approach in navigating these complex transactions has been crucial in optimizing and advancing our projects under this new regulatory landscape.”
The McDermott energy and project finance team was led by partners Carl Fleming, Philip Tingle, Heather Cooper, Jim Salerno and Seth Doughty with support from associates Andrew Kim, Garrett Brann and Olivia Johnson.
Working closely with Apex’s leading finance team, McDermott’s Energy and Project Finance team brought extensive IRA, tax credit and tax equity finance experience to the transaction. McDermott was the first law firm to close a post-IRA tax credit transfer in January 2023 and has since closed over 55 post-IRA tax credit transfer driven transactions.
Read Apex’s announcement.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

COVERAGE
June 14, 2024
Read time: 2 min

COVERAGE
June 28, 2024
Read time: 2 min

COVERAGE
June 27, 2024
Read time: 2 min

COVERAGE
June 28, 2024
Read time: 2 min